Henry Barton, Global Safety Lead at Grünenthal 

Henry Barton is a physician and pharmacovigilance expert with a expertise in surgery, anesthesiology and drug safety. He has over a decade of hands-on experience in various clinical settings, including intensive care and emergency medicine.   

As a Global Safety Lead at Grünenthal, Henry oversees the pharmacovigilance activities around several post-marketing products, such as esomeprazole and zolmitriptan. He is also responsible for designing and implementing risk management strategies, including innovative software solutions, which simplify workflows and enhances the efficiency of drug safety monitoring and risk mitigation. He is also involved in the creation and submission of risk management plans, with a special focus on the anonymization of privacy-sensitive data and the protection of confidential corporate information. Furthermore, Henry has an interest in benefit-risk methodology and its use to navigate complex assessments that confirm the positive benefit-risk balance of medicinal products.